Skip to content
  • Global Key Solutions is now KeyPedia →
  • Independent Study of FDA Correspondence Finds Earliest CDER Warning Letter Citing AI Use →
  • KeyPedia Launches openFDA MCP Connector With an "Elsa for Industry" Approach →
  • KeyPedia Listed in TPRA’s TPRM Tools List →
  • Global Key Solutions is now KeyPedia →
  • Independent Study of FDA Correspondence Finds Earliest CDER Warning Letter Citing AI Use →
  • KeyPedia Launches openFDA MCP Connector With an "Elsa for Industry" Approach →
  • KeyPedia Listed in TPRA’s TPRM Tools List →
KeyPediaKeyPedia
  • Company
  • Platform
  • Media
  • KeyPedia Lite
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. IPR Pharmaceuticals, Inc.
483•IPR Pharmaceuticals, Inc.•June 14, 2018

IPR Pharmaceuticals, Inc. – FDA 483, Jun 14, 2018

Record Details

An FDA inspection of IPR Pharmaceuticals, Inc. in Canovanas, PR, revealed a significant deficiency in control procedures for manufacturing processes. The firm failed to establish adequate controls for processes that could cause variability in in-process material and drug product characteristics. This was evidenced by temperature and humidity excursions affecting Crestor 10mg core tablets, leading to out-of-trend results for assay and degradation products, without sufficient stability data or monitoring to support product release.

Company
IPR Pharmaceuticals, Inc.
Inspection date
June 14, 2018
Product type
drugs
Office
Division of Human and Animal Food Operations - East IV
Person
  • Laurimer Kuilan-Torres

ID · 6167fbc9-2e2d-4eb3-9d94-b1d46f975693

Other documents for IPR Pharmaceuticals, Inc.

3
Document
Warning Letter · June 10, 2025 
Warning Letter · August 31, 2020 
Complete Response Letter · Undated 

With this document

Form 483 · June 14, 2018

IPR Pharmaceuticals, Inc.

  • The source document, to download any time
  • Yours for life in your Library
  • One-time purchase, no subscription. All sales final.

Comes with the profile

KRA (KeyPedia Risk Analysis)

How likely the FDA is to take enforcement action in the next 12 months.

Example18-month trend

Example5470Elevated90Higher18 months agoToday
The real score for IPR Pharmaceuticals, Inc. comes with its profile, not with a single document. How to get it

Form 483 · June 14, 2018

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Have an account? Sign in

Or discuss it with

What you get

  1. A document

    One file.

    • One FDA document, such as a Form 483
    • Yours for life in your Library
    • Each has its own price

    Your cart

    Your cart is empty.

    Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

    Browse documents
  2. The profile

    All the documents, plus intelligence about the company.

    • Every IPR Pharmaceuticals, Inc. document on file
    • The KRA score, which a single document does not include
    • Observations and inspection history
  3. Access

    This, for every company on KeyPedia.

    • Combine profiles in one search
    • Search across any modality: products, industry types, drugs, devices and recalls
    • Track everything as it changes
    • Other agencies too, such as EMA, Health Canada and UK MHRA
    here
KeyPedia
The intelligence layer for life sciences
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
Quick Links
HomePlatformUse CasesHardwarePricingResearchOur TechnologyFAQMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPrograms & Partnerships
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.